Yong H. Jeon

Daegu, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 82 publications

Development and Biological Evaluation of a GLUT-Inhibiting Theranostic Agent, MF48, for Colorectal Cancer Therapy.

Development and Biological Evaluation of a GLUT-Inhibiting Theranostic Agent, MF48, for Colorectal Cancer Therapy.

Journal: ACS applied bio materials

Published: June 18, 2026

Natural killer cells labeled with radionuclide-embedded double-layer gold nanoparticles conjugated to a mitochondrial localization sequence for PET/CT imaging and NK cell-based immunotherapy.

Natural killer cells labeled with radionuclide-embedded double-layer gold nanoparticles conjugated to a mitochondrial localization sequence for PET/CT imaging and NK cell-based immunotherapy.

Journal: Nanomedicine (London, England)

Published: April 15, 2026

Design, Synthesis and Biological Evaluation of Pyrazolopyrimidine Derivatives as Aryl Hydrocarbon Receptor Antagonists for Colorectal Cancer Immunotherapy.

Design, Synthesis and Biological Evaluation of Pyrazolopyrimidine Derivatives as Aryl Hydrocarbon Receptor Antagonists for Colorectal Cancer Immunotherapy.

Journal: Pharmaceutics

Published: September 10, 2025

Correction: Kalimuthu et al. Regulated Mesenchymal Stem Cells Mediated Colon Cancer Therapy Assessed by Reporter Gene Based Optical Imaging. Int. J. Mol. Sci. 2018, 19, 1002.

Correction: Kalimuthu et al. Regulated Mesenchymal Stem Cells Mediated Colon Cancer Therapy Assessed by Reporter Gene Based Optical Imaging. Int. J. Mol. Sci. 2018, 19, 1002.

Journal: International journal of molecular sciences

Published: August 15, 2025

Regio- and Stereoselective Ribose Modification in Truncated 2,8-Disubstituted Adenosine Scaffold to Develop Highly Potent A2A Adenosine Receptor Antagonists.

Regio- and Stereoselective Ribose Modification in Truncated 2,8-Disubstituted Adenosine Scaffold to Develop Highly Potent A2A Adenosine Receptor Antagonists.

Journal: Journal of medicinal chemistry

Published: July 28, 2025

N-Methyl-D-aspartate receptors as novel M1 macrophage-specific biomedical imaging nanoplatform agents: feasibility of targeted imaging in an inflammatory mice model.

N-Methyl-D-aspartate receptors as novel M1 macrophage-specific biomedical imaging nanoplatform agents: feasibility of targeted imaging in an inflammatory mice model.

Journal: Journal of materials chemistry. B

Published: July 10, 2025

Exploring the Therapeutic Potential of Estrogen-Related Receptor γ Inverse Agonists in Atopic Dermatitis-like Lesions.

Exploring the Therapeutic Potential of Estrogen-Related Receptor γ Inverse Agonists in Atopic Dermatitis-like Lesions.

Journal: International journal of molecular sciences

Published: June 24, 2025

Establishment of an Orthotopic and Metastatic Colorectal Cancer Mouse Model Using a Tissue Adhesive-Based Implantation Method.

Establishment of an Orthotopic and Metastatic Colorectal Cancer Mouse Model Using a Tissue Adhesive-Based Implantation Method.

Journal: Cancers

Published: June 08, 2025

In vivo pharmacokinetics, therapeutic efficacy and immune response of bacteriophage vB_AbaSt_W16 against carbapenem-resistant Acinetobacter baumannii.

In vivo pharmacokinetics, therapeutic efficacy and immune response of bacteriophage vB_AbaSt_W16 against carbapenem-resistant Acinetobacter baumannii.

Journal: JAC-antimicrobial resistance

Published: March 31, 2025

Vitexicarpin suppresses colorectal and non-small cell lung cancer via selective inhibition of Anoctamin 1.

Vitexicarpin suppresses colorectal and non-small cell lung cancer via selective inhibition of Anoctamin 1.

Journal: Frontiers in pharmacology

Published: January 08, 2025

Synthesis and Biological Evaluation of Peripheral HTR2A Antagonists for Colorectal Cancer.

Synthesis and Biological Evaluation of Peripheral HTR2A Antagonists for Colorectal Cancer.

Journal: Journal of medicinal chemistry

Published: January 06, 2025

Inhibition of FOS-Like Antigen 1 Reduces Chemoresistance to Temozolomide Through Stemness Reprogramming via IL-6/STAT3Tyr705 Pathway.

Inhibition of FOS-Like Antigen 1 Reduces Chemoresistance to Temozolomide Through Stemness Reprogramming via IL-6/STAT3Tyr705 Pathway.

Journal: MedComm

Published: November 13, 2024

Showing 1-12 of 82

Last Updated: 09/26/2026